Genmab Profit Margin

The latest profit margin for GMAB is 10.32% as of March 2026. That compares with 37.1% in the prior-year period — down 72.2% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Genmab's historical trend and sector peers before judging valuation or financial health.

Over the past year, GMAB's profit margin moved from 37.1% to 10.32% — a 72.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Genmab's valuation or profitability profile.

Against Healthcare companies, GMAB currently prints 10.32% for profit margin, while the sector average sits near 15.29%. That is roughly 32.5% below the sector mean. Large gaps often invite a closer look at Genmab's growth, margins, and balance sheet.

Profit Margin shows how effectively Genmab converts resources into returns. At 10.32%, GMAB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 37.1% in the prior-year period — down 72.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GMAB's profit margin (10.32%), review year-over-year change from 37.1%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.